
Oncology NEWS International
- Oncology NEWS International Vol 15 No 6
- Volume 15
- Issue 6
CA4P Gets Orphan Drug Status
The FDA has granted Oxigene's combretastatin A4P (CA4P) orphan drug status for treatment of ovarian cancer. In a phase Ib trial, advanced ovarian cancer patients who had failed previous therapy showed a 67% response rate to CA4P plus carboplatin and paclitaxel, the company said in a news release. This combination is currently being evaluated in a phase II trial in women with platinum-resistant ovarian cancer.
Waltham, MassThe FDA has granted Oxigene's combretastatin A4P (CA4P) orphan drug status for treatment of ovarian cancer. In a phase Ib trial, advanced ovarian cancer patients who had failed previous therapy showed a 67% response rate to CA4P plus carboplatin and paclitaxel, the company said in a news release. This combination is currently being evaluated in a phase II trial in women with platinum-resistant ovarian cancer.
Articles in this issue
about 20 years ago
Triple-Negative Cancers More Common in Young Black Ptsabout 20 years ago
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'about 20 years ago
Study to Examine Outcomes Disparities in Pediatric ALLabout 20 years ago
Thalidomide Has 'Changed the Paradigm' in Myeloma Rxabout 20 years ago
Testicular Ca Survivors at Increased Risk for CV Eventsabout 20 years ago
A Novel Brings a Cancer Research Laboratory to Lifeabout 20 years ago
NCCN Reveals New Venous Thromboembolism Guidelineabout 20 years ago
Lapatinib New Option for Metastatic HER2+ Breast Caabout 20 years ago
FDA Approves Dacogen for Treating All MDS Subtypesabout 20 years ago
Noninvasive Ablation Relieves Chronic Chest Wall Pain









































































